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Summary 1 
Different classes of BRAF mutations are present in colorectal and other cancers. 2 
Non-V600 mutations are rare; however, their detection rate will increase as the use 3 
of next-generation sequencing ramps up quickly in clinical practice.  Different 4 
biochemical signalling pathways are active in non-V600 BRAF mutant cancers and 5 
may affect treatment response.  6 
 7 
 8 
Main Text 9 
 10 
In this issue of Clinical Cancer Research, Yaeger and colleagues (1) investigated 11 
whether patients with different classes of non-V600 BRAF mutant colorectal cancer 12 
(CRC) might benefit from anti-epidermal growth factor receptor (EGFR) therapies.  13 
They suggested that class-2 non-V600 BRAF mutant tumours do not respond while 14 
class-3 non-V600 BRAF mutant tumours are more likely to respond to EGFR 15 
inhibition. 16 
 17 
The importance of BRAF mutations is increasingly recognised in CRC: firstly, in view 18 
of the poor prognostic role in advanced disease; secondly, as negative predictive 19 
biomarker of response to anti-EGFR therapies and to single agent BRAF-inhibitors; 20 
and lastly, because of the recently established role in predicting response to 21 
chemotherapy-free combinations of cetuximab, encorafenib with or without 22 
binimetinib (1, 2).  However, these findings currently apply exclusively to the most 23 
common BRAF mutation (V600E), highlighting that not all BRAF mutations are the 24 
same. 25 
  26 
Non-V600 BRAF mutations are rare, occurring in about 2% of the metastatic CRC 27 
population (3).  Comparison of their clinical and prognostic associations with those of 28 
classical V600E BRAF mutant tumours was previously performed in a retrospective 29 
analysis of more than 9600 patients (3).  The less aggressive phenotype and 30 
significantly longer survival compared to V600E BRAF mutation carriers was 31 
described, justifying the potential need for different therapeutic strategies.  These 32 
findings have been recently echoed by Schirippa and colleagues (4) who also 33 
described substantial differences in gene expression profiling, with non-V600 BRAF 34 
mutations exclusively presenting an epithelial-like profile, in contrast to V600E BRAF 35 
mutant tumours where the inflammatory profile is usually the most common one. 36 
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Even between non-V600 BRAF mutant tumours heterogeneity exists.  A number of 1 
elegant pre-clinical studies have dissected biochemical properties specific to 2 
individual classes of non-V600 BRAF mutations (5) (Figure 1), however, attempts to 3 
correlate BRAF variants with clinical outcome have been hampered by the relative 4 
rarity of these mutations.  Hence, Yaeger and colleagues established a large 5 
clinically annotated database of patients whose tumours were found to carry a non-6 
V600 BRAF alteration in sequencing studies in multiple US and Japanese institutions 7 
(1).  8 
 9 
Up to 153 patients were identified, with 5 of them carrying a non-V600 BRAF 10 
mutation not previously fully characterized.  Therefore, for the very first time the 11 
effect of these 5 non-V600 BRAF mutations on downstream proteins of the phospho-12 
ERK and phospho-MEK pathway was described using mouse embryonic fibroblasts. 13 
Four patient-derived xenograft models were also established and assessed for anti-14 
EGFR sensitivity.  In one of them, carrying a D594N BRAF mutation (class 3), 15 
treatment with cetuximab clearly demonstrated growth inhibition.  This mutation 16 
appeared to confer a much less aggressive phenotype when compared to the other 3 17 
models, with tumour volumes still quite small two weeks post-inoculation and slower 18 
increments in the vehicle-treated group.  This is in line with the good prognostic value 19 
of this mutation previously described in CRC patients (6).  Conversely, the G466V 20 
model (also class 3) demonstrated a very aggressive phenotype with high tumour 21 
volume at baseline and doubling-times of less than 10 days, which possibly led to 22 
experiment termination just before 20 days, much earlier than D594N (class 3) and 23 
K601E (class 2).  The last model (T599dup, class 2) seemed also associated with 24 
more aggressive phenotype with high tumour volume in the vehicle treated group 25 
and some level of response demonstrated in the cetuximab treated group.  26 
 27 
Prompted by the pre-clinical observation that different non-V600 BRAF mutations 28 
may confer variable degrees of sensitivity to anti-EGFR treatments, the authors 29 
tested the predictive/prognostic value of class 2 and class 3 BRAF mutations in CRC 30 
patients treated with EGFR inhibitors.  The results suggested that class 2 mutation 31 
carriers have limited or no benefit while patients whose tumour harbour a class 3 32 
mutation show 50% response rate with some durable responses when treated with 33 
anti-EGFR monoclonal antibodies (1).  These observations are certainly intriguing 34 
and hypothesis-generating but do not completely align with currently available 35 
literature in the field.  Jonhson et al. evaluated the association between atypical 36 
BRAF mutations and response to EGFR inhibitors and found no complete or partial 37 
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responses in any of the eleven non-V600 BRAF mutant patients in their cohort; 1 
among the six patients with stable disease, four were class 3, one was class 2 and 2 
one unknown suggesting a very limited benefit for EGFR inhibitors in non-V600 3 
BRAF mutant CRC patients in general (7).  In a different report, Wang et al. observed 4 
a partial response to single agent panitumumab in a KRAS wild-type BRAF G469V (class 5 
2) mutant CRC patient (8).  6 
 7 
Several confounding factors may account for the heterogeneous pattern of response 8 
to EGFR inhibitors observed across the different studies (1,7-8).  Indeed, the small 9 
number of patients, the frequent use of EGFR monoclonal antibodies in combination 10 
with chemotherapy, the presence of different chemotherapy backbones, the 11 
unbalanced number of previous therapies (with different expected response rates 12 
according to line of treatment) and the absence of a control group may well justify 13 
discordant findings in these reports. 14 
 15 
The use of next-generation platforms based on extended targeted panels or whole 16 
exome sequencing is rapidly growing in routine clinical practice thus we should 17 
expect an increase in the detection of relatively rare non-V600 BRAF mutations in 18 
CRC patients.  While the prospective collection of well-annotated datasets may, in 19 
future, help to clarify the predictive value of these classes of mutations, several 20 
questions relative to the clinical value of non-V600 BRAF mutants in current clinical 21 
practice remain.  Should clinicians take into account the occurrence of non-V600 22 
BRAF mutation in their decisional algorithm?  Do the data from Yaeger and 23 
colleagues provide a framework to design future clinical trials in this setting? 24 
 25 
In our opinion, current evidence is not robust enough to justify the use of class 2 26 
BRAF mutations as negative biomarkers for the selection of CRC patients’ candidate 27 
for EGFR monoclonal antibodies.  Class 2 mutations represent a small subgroup 28 
within the already rare population of non-V600 BRAF CRC.  Due to conflicting data 29 
on their predictive value, and lack of definitive evidence confirming that the addition 30 
of EGFR monoclonal antibodies has a detrimental effect in these patients, omitting 31 
anti-EGFR therapies cannot be recommended.  As suggested by the authors (1), 32 
future trials should tackle the biology underpinning class 2 BRAF mutations and test 33 
type II RAF inhibitors or the combination of cetuximab and MEK inhibitors in order to 34 
improve outcome in this subset of patients.  35 
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Class 3 mutations co-occur with RAS mutations in more than 30% of cases and, in 1 
this scenario, the presence or absence of a RAS mutation would dictate the clinician 2 
decision to add anti-EGFR agents.  In those patients with RAS wild-type and class 3 3 
BRAF mutations that rely on receptor tyrosine kinase activation, anti-EGFR 4 
monoclonal antibodies can be considered.  In this context, sequencing or multi-omics 5 
analyses may identify actionable drivers that could be targeted using EGFR, MET or 6 
MEK inhibitors alone or in combination and future trials should move in this direction. 7 
 8 
In summary, even though the retrospective nature of the study and some caveats in 9 
the design prevent from drawing firm conclusions, the study reported by Yaeger and 10 
colleagues highlights the paramount importance of reverse translation studies 11 
matching clinical and pre-clinical data to identify molecular vulnerabilities and inform 12 
the design of future trials opening the way to diversified therapeutic approaches in 13 
class 2 and class 3 non-V600 BRAF mutant patients. 14 
 15 
 16 
 17 
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Figure 1.  Signalling pathways in different classes of BRAF mutations.  V600 21 
BRAF mutations (Class 1) are independent of RAS signalling and work as 22 
monomers. Non-V600 Class 2 BRAF mutants are also independent of RAS but 23 
signal as constitutive dimers. Non-V600 Class 3 BRAF mutations have low or no 24 
kinase activity and depend on RAS activation acting as amplifiers of the RAS 25 
signalling pathway. 26 
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